氯吡格雷抵抗：未来之路。
Clopidogrel resistance: the way forward.
作者信息
Ray Shuvanan
机构信息
Chief of Interventional Cardiology, Fortis Hospitals Limited, 730 Anandapur, Beside Calcutta International School, EM Bypass, Kasba, East Kolkata Township, Kolkata 700107, India.
出版信息
Indian Heart J. 2014 Sep-Oct;66(5):530-4. doi: 10.1016/j.ihj.2014.08.012. Epub 2014 Oct 7.
Abstract
Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of Stent Thrombosis. This review article tries to find out the causes of Clopidogrel Resistance, the main factors involving it, Laboratory evaluation of Clopidogrel Resistance. The overall incidence of Clopidogrel Resistance across the Globe & India has also been considered. The article also discusses the clinical significance of Clopidogrel Resistance & its relationship with adverse cardiovascular events. This review ends with the probable solutions to Clopidogrel Resistance & the new generation of antiplatelets which can be used for the same.
摘要
氯吡格雷，一种第二代噻吩并吡啶，十多年来一直是急性冠状动脉综合征（ACS）治疗的主要药物。氯吡格雷抵抗与ACS患者死亡率增加及支架血栓形成数量增多有关。这篇综述文章试图找出氯吡格雷抵抗的原因、涉及的主要因素、氯吡格雷抵抗的实验室评估。还考虑了全球及印度氯吡格雷抵抗的总体发生率。文章还讨论了氯吡格雷抵抗的临床意义及其与不良心血管事件的关系。这篇综述最后提出了氯吡格雷抵抗可能的解决方案以及可用于此的新一代抗血小板药物。
相似文献
1
Clopidogrel resistance: the way forward.
Indian Heart J. 2014 Sep-Oct;66(5):530-4. doi: 10.1016/j.ihj.2014.08.012. Epub 2014 Oct 7.
2
Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome.
J Cardiovasc Nurs. 2013 Sep-Oct;28(5):483-94. doi: 10.1097/JCN.0b013e31826173ba.
3
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Am J Cardiol. 2013 Aug 1;112(3):355-62. doi: 10.1016/j.amjcard.2013.03.036. Epub 2013 Apr 27.
4
Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome.
Indian Heart J. 2007 Mar-Apr;59(2):152-6.
5
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Med Sci Monit. 2009 Dec;15(12):MS24-30.
6
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Postgrad Med. 2013 Jul;125(4):91-102. doi: 10.3810/pgm.2013.07.2682.
7
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001.
8
Prasugrel: a critical comparison with clopidogrel.
Pharmacotherapy. 2009 Dec;29(12):1441-51. doi: 10.1592/phco.29.12.1441.
9
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Am Heart J. 2009 Sep;158(3):e21-6. doi: 10.1016/j.ahj.2009.06.021.
10
Ticagrelor: a novel reversible oral antiplatelet agent.
Cardiol Rev. 2011 Mar-Apr;19(2):95-100. doi: 10.1097/CRD.0b013e3182099d86.
引用本文的文献
1
Evaluation of clopidogrel responsiveness using the Platelet Function Analyzer-200 (PFA-200) in dogs.
Front Vet Sci. 2025 Jul 11;12:1595147. doi: 10.3389/fvets.2025.1595147. eCollection 2025.
2
Platelet aggregation rate serves as a significant predictive indicator for thromboembolic events in the context of stent-assisted embolization for unruptured arterial aneurysms.
Front Neurol. 2025 May 1;16:1538753. doi: 10.3389/fneur.2025.1538753. eCollection 2025.
3
The frequencies of CYP2C19*2, *3, and *17 alleles and their impact on the clinical efficacy of doubled maintenance dose of clopidogrel in Syrian patients with coronary artery disease.
BMC Cardiovasc Disord. 2025 Apr 28;25(1):330. doi: 10.1186/s12872-025-04768-8.
4
Evaluation of response to clopidogrel in patients with CYP2C19*2/*3 polymorphisms and its association with miR-19b expression.
Mol Biol Rep. 2025 Apr 9;52(1):374. doi: 10.1007/s11033-025-10482-7.
5
In Vitro Analysis of AKR1D1 Interactions with Clopidogrel: Effects on Enzyme Activity and Gene Expression.
Balkan J Med Genet. 2025 Mar 6;27(2):69-75. doi: 10.2478/bjmg-2024-0012. eCollection 2024 Dec.
6
Breaking boundaries: Ticagrelor monotherapy in high-risk patients.
Int J Cardiol Heart Vasc. 2024 Oct 20;55:101526. doi: 10.1016/j.ijcha.2024.101526. eCollection 2024 Dec.
7
Optimized Methodology to Produce Platelet-Rich Plasma and Perform Platelet Aggregation in Patients With Coronary Artery Disease.
Cureus. 2024 Sep 9;16(9):e69032. doi: 10.7759/cureus.69032. eCollection 2024 Sep.
8
Left Atrial Appendage Closure: A Current Overview Focused on Technical Aspects and Different Approaches.
Rev Cardiovasc Med. 2022 Apr 26;23(5):155. doi: 10.31083/j.rcm2305155. eCollection 2022 May.
9
Clopidogrel Resistance in Ischemic Stroke Patients.
Ann Indian Acad Neurol. 2024 Sep 1;27(5):493-497. doi: 10.4103/aian.aian_79_24. Epub 2024 Jul 24.
10
Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome.
Indian Heart J. 2024 Jul-Aug;76(4):268-270. doi: 10.1016/j.ihj.2024.07.003. Epub 2024 Jul 14.
本文引用的文献
1
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Platelets. 2013;24(4):297-302. doi: 10.3109/09537104.2012.693992. Epub 2012 Jun 21.
2
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Circulation. 2011 Sep 6;124(10):1132-7. doi: 10.1161/CIRCULATIONAHA.111.029165. Epub 2011 Aug 29.
3
Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Epub 2011 Aug 2.
4
Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
JACC Cardiovasc Interv. 2011 Apr;4(4):403-10. doi: 10.1016/j.jcin.2010.12.011.
5
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4.
6
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
Circulation. 2010 Mar 16;121(10):1188-99. doi: 10.1161/CIRCULATIONAHA.109.919456. Epub 2010 Mar 1.
7
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Thromb Haemost. 2010 Jan;103(1):213-23. doi: 10.1160/TH09-07-0482. Epub 2009 Oct 26.
8
Platelet inhibition with cangrelor in patients undergoing PCI.
N Engl J Med. 2009 Dec 10;361(24):2318-29. doi: 10.1056/NEJMoa0908628.
9
Dual antiplatelet drug resistance in patients with acute coronary syndrome.
Indian Heart J. 2009 Jan-Feb;61(1):68-73.
10
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
Zotero 插件